The Effect of Intratumoral Interrelation Among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 May 14

PMID 35565267

Authors

Noriko Goda

Chika Nakashima

Ichiro Nagamine

Sunao Otagaki

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is characterized by an active immune response. We evaluated intratumoral interrelation between FOXP3+ tumor-infiltrating lymphocytes and other cytokines in TNBC. Network analysis refined cytokines significantly correlate with FOPX3 in TNBC. Information on the treatment response and prognosis of patients, and survival data from the TGCA and METABRIC databases were analyzed according to refined cytokines. Interleukin (IL)-33 was significantly expressed by TNBC cell lines compared to luminal cell lines (log2 fold change: 5.31, p < 0.001) and IL-33 and TGFB2 showed a strong correlation with FOXP3 in the TNBC cell line. Immunohistochemistry demonstrated that the IL-33 high group was a significant predictor of complete response of neoadjuvant chemotherapy (odds ratio (OR) 4.12, p < 0.05) and favorable survival compared to the IL-33 low group (OR 6.48, p < 0.05) in TNBC. Survival data from TGCA and METABRIC revealed that FOXP3 was a significantly favorable marker in the IL-33 high group compared to the low IL-33 low group (hazard ratio (HR) 2.1, p = 0.02), and the IL-33 high/TGFB2 high subgroup showed significant favorable prognosis in the FOXP3 high group compared to the FOPX3 low group in TNBC (HR 3.5, p = 0.01). IL-33 and TGFB2 were key cytokines of intratumoral interrelation among FOXP3 in TNBC.

Citing Articles

Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.

de Moraes F, Cavalcanti Souza M, Sano V, Moraes R, Melo A Clin Transl Oncol. 2024; .

PMID: 39154313 DOI: 10.1007/s12094-024-03661-8.

The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy.

Nicolini A, Ferrari P, Silvestri R, Gemignani F J Natl Cancer Cent. 2024; 4(1):14-24.

PMID: 39036381 PMC: 11256721. DOI: 10.1016/j.jncc.2024.01.004.

Decoding the IL-33/ST2 Axis: Its Impact on the Immune Landscape of Breast Cancer.

Stojanovic B, Gajovic N, Jurisevic M, Dimitrijevic Stojanovic M, Jovanovic M, Jovanovic I Int J Mol Sci. 2023; 24(18).

PMID: 37762328 PMC: 10531367. DOI: 10.3390/ijms241814026.

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.

Abuhadra N, Sun R, Yam C, Rauch G, Ding Q, Lim B Cancers (Basel). 2023; 15(13).

PMID: 37444385 PMC: 10339918. DOI: 10.3390/cancers15133275.

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.

van den Ende N, Nguyen A, Jager A, Kok M, Debets R, van Deurzen C Int J Mol Sci. 2023; 24(3).

PMID: 36769287 PMC: 9918290. DOI: 10.3390/ijms24032969.

References

Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V . The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma . Oncoimmunology. 2016; 5(10):e1218106. PMC: 5087306. DOI: 10.1080/2162402X.2016.1218106. View

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

Baretta Z, Mocellin S, Goldin E, Olopade O, Huo D . Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(40):e4975. PMC: 5059054. DOI: 10.1097/MD.0000000000004975. View

Bates G, Fox S, Han C, Leek R, Garcia J, Harris A . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. DOI: 10.1200/JCO.2006.05.9584. View

Li X, Yang J, Peng L, Sahin A, Huo L, Ward K . Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2016; 161(2):279-287. DOI: 10.1007/s10549-016-4059-6. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Yeong J, Thike A, Lim J, Lee B, Li H, Wong S . Higher densities of Foxp3 regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017; 163(1):21-35. DOI: 10.1007/s10549-017-4161-4. View

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B . Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008; 14(8):2413-20. DOI: 10.1158/1078-0432.CCR-07-4491. View

Liu F, Lang R, Zhao J, Zhang X, Pringle G, Fan Y . CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011; 130(2):645-55. DOI: 10.1007/s10549-011-1647-3. View

10.

Colaprico A, C Silva T, Olsen C, Garofano L, Cava C, Garolini D . TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015; 44(8):e71. PMC: 4856967. DOI: 10.1093/nar/gkv1507. View

11.

deLeeuw R, Kost S, Kakal J, Nelson B . The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012; 18(11):3022-9. DOI: 10.1158/1078-0432.CCR-11-3216. View

12.

Robson M, Tung N, Conte P, Im S, Senkus E, Xu B . OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019; 30(4):558-566. PMC: 6503629. DOI: 10.1093/annonc/mdz012. View

13.

Savas P, Salgado R, Denkert C, Sotiriou C, Darcy P, Smyth M . Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2015; 13(4):228-41. DOI: 10.1038/nrclinonc.2015.215. View

14.

Li C, Karantza V, Aktan G, Lala M . Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 2019; 21(1):143. PMC: 6916124. DOI: 10.1186/s13058-019-1210-4. View

15.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

16.

Zhang L, Wang X, Ding J, Sun Q, Zhang S . The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Ann Diagn Pathol. 2019; 40:143-151. DOI: 10.1016/j.anndiagpath.2019.04.004. View

17.

Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S . Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015; 17:124. PMC: 4560879. DOI: 10.1186/s13058-015-0632-x. View

18.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25(8):1544-50. DOI: 10.1093/annonc/mdu112. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Stanton S, Disis M . Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016; 4:59. PMC: 5067916. DOI: 10.1186/s40425-016-0165-6. View